Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Charite University, Berlin, Germany
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
JSehouli, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT01600573
First received: May 9, 2012
Last updated: October 10, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)